Lumos Pharma Announces Participation in Investor Conferences in September
08 September 2023 - 6:34AM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for moderate Pediatric
Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials,
announced that the Company will participate in the H.C. Wainwright
25th Annual Global Investment Conference being held September 11th
– 13th and the Cantor Global Healthcare Conference 2023 being held
September 26th – 28th in New York City. Lumos Pharma management
will present and host one-on-one meetings at both conferences.
H.C. Wainwright 25th Annual Global
Investment Conference: September 11th
– 13th
|
Title: |
Lumos Pharma Corporate Presentation (On-Demand) |
|
Date/Time: |
September 11th at 7:00AM EDT |
|
Webcast Link: |
Register here |
|
|
|
Cantor Global Healthcare Conference
2023: September 26th
-28th
|
Title: |
Lumos Pharma Fireside Chat |
|
Date/Time: |
September 28th at 1:15PM EDT |
|
Webcast Link: |
Register here |
|
|
|
The webcasts for both conferences can also be found on the
Company’s website under Events & Presentations in the Investors
& Media section. A replay of both presentations will be
available for 90 days thereafter. Please contact your conference
salesperson or Lumos Pharma Investor Relations to schedule
one-on-one meetings with the management team.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company
focused on the development and commercialization of therapeutics
for rare diseases. The Company was founded and is led by a
management team with longstanding experience in rare disease drug
development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is
a novel, oral growth hormone (GH) secretagogue, seeking to
transform the $4.5B global GH market from injectable to oral
therapy. LUM-201 is currently being evaluated in multiple Phase 2
clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and
has received Orphan Drug Designation in both the US and EU. For
more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From Apr 2024 to May 2024
Lumos Pharma (NASDAQ:LUMO)
Historical Stock Chart
From May 2023 to May 2024